Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    Acute Unilateral Vestibulopathy
Previous Study | Return to List | Next Study

Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03110458
Recruitment Status : Completed
First Posted : April 12, 2017
Last Update Posted : May 13, 2020
Sponsor:
Information provided by (Responsible Party):
Sensorion

Brief Summary:
A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose-regimens of orally administered SENS-111 (100mg and 200mg) given during 4 days in patients suffering from Acute Unilateral Vestibulopathy (AUV)

Condition or disease Intervention/treatment Phase
Acute Unilateral Vestibulopathy (AUV) Drug: SENS-111 100mg Drug: SENS-111 200mg Drug: Placebo Oral Tablet Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 107 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 2 Dose Regimens of Orally Administered SENS-111 (100 mg and 200 mg) Given During 4 Days in Patients Suffering From Acute Unilateral Vestibulopathy
Actual Study Start Date : April 12, 2017
Actual Primary Completion Date : October 15, 2019
Actual Study Completion Date : October 15, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: SENS-111 100mg
SENS-111 100mg: 2ODT (1 ODT SENS-111 and 1 ODT placebo)
Drug: SENS-111 100mg
2 ODT (1 ODT SENS-111 and 1 ODT placebo)

Experimental: SENS-111 200mg
SENS-111 200mg: 2 ODTs SENS-111
Drug: SENS-111 200mg
2 ODT (2 ODT SENS-111)

Placebo Comparator: Placebo
Placebo: 2 placebo ODTs
Drug: Placebo Oral Tablet
2 ODT (2 ODT placebo)




Primary Outcome Measures :
  1. Standing vertigo intensity [ Time Frame: Up to 28 days ]
    By Visual analogue scale (VI-VAS)


Secondary Outcome Measures :
  1. Worst spontaneous vertigo intensity [ Time Frame: Up to 28 days ]
    By Visual analogue scale

  2. Proprioception [ Time Frame: Up to 28 days ]
    By the score of the Romberg tests

  3. Vestibular spontaneous nystagmus [ Time Frame: Up to 28 days ]
    By oculography

  4. Nausea severity [ Time Frame: Up to 28 days ]
    By Visual Analogue Scale

  5. Safety [ Time Frame: Up to 28 days ]
    By the incidence of adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria includes, but is not limited to:

* Subject has a diagnosis of definite Acute Unilateral Vestibulopathy

Exclusion criteria includes, but is not limited to:

  • Acute continuous vertigo lasting more than 72 hours prior to randomization
  • History of acute or chronic vestibular diseases
  • History of prior acute central vestibular lesion
  • Acute or chronic disease of middle ear

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03110458


Locations
Layout table for location information
Germany
STRUPP
Munich, Germany
Sponsors and Collaborators
Sensorion
Investigators
Layout table for investigator information
Principal Investigator: Michael STRUPP, MD University Hospital Munich
Layout table for additonal information
Responsible Party: Sensorion
ClinicalTrials.gov Identifier: NCT03110458    
Other Study ID Numbers: SENS 111-201
First Posted: April 12, 2017    Key Record Dates
Last Update Posted: May 13, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sensorion:
Acute unilateral vestibulopathy, AUV
Additional relevant MeSH terms:
Layout table for MeSH terms
Stress, Psychological
Behavioral Symptoms